Medication info
Sebaco HCT Tablet 10/40/12.5mg

Sebaco HCT Tablet 10/40/12.5mg

Prescription medicationTabletOral
Ingredient · strength
Olmesartan Medoxomil›40mg / 1 tabletAmlodipine Besylate›13.888mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Aju Pharmaceutical Co., Ltd.
Appearance
Grayish-red round film-coated tablets
Packaging
30 tablets/box [10 tablets/Alu-Alu*3]
Approval status
Active

MFDS item code 201906791 · Approved 2019.09.25 · Insurance code 654005530

Summary

Main use
Treatment of essential hypertension not controlled with amlodipine and olmesartan in combination
Who takes it
Adults · Children
Adult dose
Take 1 tablet once daily with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before administering this drug, it is recommended that the dose be adjusted using the individual components (olmesartan medoxomil and amlodipine as monotherapy or combination therapy). However, if blood pressure is not controlled with combination therapy of amlodipine and olmesartan medoxomil as follows, switching directly to this drug may be considered. The maximum dose of this drug is 10/40/25mg of amlodipine/olmesartan medoxomil/hydrochlorothiazide. Since the maximum blood pressure-lowering effect occurs within 2 weeks after administration, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20/12.5mg: Administer to patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/20mg. - 5/40/12.5mg: Administer to patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/40mg or with this drug 5/20/12.5mg. - 5/40/25mg: Administer to patients whose blood pressure is not adequately controlled with this drug 5/40/12.5mg. - 10/40/12.5mg: Administer to patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 10/40mg or with this drug 5/40/12.5mg. - 10/40/25mg: Administer to patients whose blood pressure is not adequately controlled with this drug 5/40/25mg or this drug 10/40/12.5mg. ※ Refer to the following dose escalation schedule. (The content of each component is listed in the order of amlodipine/olmesartan medoxomil/hydrochlorothiazide.) 5/20/0mg → 5/20/12.5mg ↓ 5/40/0mg → 5/40/12.5mg → 5/40/25mg ↓ ↓ 10/40/0mg → 10/40/12.5mg → 10/40/25mg Patients with renal impairment The maximum dose of this drug for patients with mild to moderate renal impairment (creatinine clearance 30-60mL/min) is 20/5/12.5 milligrams once daily. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. This drug should not be administered to patients with severe renal impairment (creatinine clearance < 30mL/min). Patients with hepatic impairment Use with caution in patients with mild to moderate hepatic impairment. The maximum dose of this drug for patients with moderate hepatic impairment is 5/20/12.5 milligrams once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment. This drug should not be administered to patients with severe hepatic impairment. Older adults (65 years or older) Treatment is generally initiated at a low dose. When adjusting the dose, the patient's renal or cardiac function and comorbidities should be taken into consideration. Blood pressure should be monitored closely and more frequently in older adults. In particular, since experience with this drug in adults 75 years of age or older is very limited, monitor very carefully when administering this drug.
Child dose
The safety and efficacy of this drug in pediatric patients under 18 years of age have not been established; therefore, its use is not recommended.

Ingredients

Manufacturer
Aju Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with amlodipine and olmesartan in combination

  • Essential hypertension
View approved original text

This drug is used for the treatment of essential hypertension through combination therapy with amlodipine and olmesartan medoxomil, effectively controlling blood pressure. This therapy helps to reduce cardiovascular burden and lower the risk of complications. It contributes to improving health through consistent blood pressure management in hypertensive patients.

How to take

Adult dose

Take 1 tablet once daily with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before administering this drug, it is recommended that the dose be adjusted using the individual components (olmesartan medoxomil and amlodipine as monotherapy or combination therapy). However, if blood pressure is not controlled with combination therapy of amlodipine and olmesartan medoxomil as follows, switching directly to this drug may be considered. The maximum dose of this drug is 10/40/25mg of amlodipine/olmesartan medoxomil/hydrochlorothiazide. Since the maximum blood pressure-lowering effect occurs within 2 weeks after administration, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20/12.5mg: Administer to patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/20mg. - 5/40/12.5mg: Administer to patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/40mg or with this drug 5/20/12.5mg. - 5/40/25mg: Administer to patients whose blood pressure is not adequately controlled with this drug 5/40/12.5mg. - 10/40/12.5mg: Administer to patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 10/40mg or with this drug 5/40/12.5mg. - 10/40/25mg: Administer to patients whose blood pressure is not adequately controlled with this drug 5/40/25mg or this drug 10/40/12.5mg. ※ Refer to the following dose escalation schedule. (The content of each component is listed in the order of amlodipine/olmesartan medoxomil/hydrochlorothiazide.) 5/20/0mg → 5/20/12.5mg ↓ 5/40/0mg → 5/40/12.5mg → 5/40/25mg ↓ ↓ 10/40/0mg → 10/40/12.5mg → 10/40/25mg Patients with renal impairment The maximum dose of this drug for patients with mild to moderate renal impairment (creatinine clearance 30-60mL/min) is 20/5/12.5 milligrams once daily. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. This drug should not be administered to patients with severe renal impairment (creatinine clearance < 30mL/min). Patients with hepatic impairment Use with caution in patients with mild to moderate hepatic impairment. The maximum dose of this drug for patients with moderate hepatic impairment is 5/20/12.5 milligrams once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment. This drug should not be administered to patients with severe hepatic impairment. Older adults (65 years or older) Treatment is generally initiated at a low dose. When adjusting the dose, the patient's renal or cardiac function and comorbidities should be taken into consideration. Blood pressure should be monitored closely and more frequently in older adults. In particular, since experience with this drug in adults 75 years of age or older is very limited, monitor very carefully when administering this drug.

Child dose

The safety and efficacy of this drug in pediatric patients under 18 years of age have not been established; therefore, its use is not recommended.

Precautions

This medication may cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy; therefore, it should be discontinued immediately if pregnancy is confirmed. It should not be taken by patients with allergies to this medication or its components, certain heart diseases, severely impaired kidney or liver function, pregnant or nursing women, and patients with specific electrolyte imbalances. In patients with reduced blood volume or low salt levels, hypotension may occur; therefore, their condition should be carefully checked before administration, and appropriate measures should be taken if hypotensive symptoms appear. Patients with impaired kidney function, kidney transplant recipients, renovascular hypertension patients, liver disease patients, and patients with certain heart valve diseases should use this medication cautiously and undergo regular blood tests and physical assessments. This drug lowers blood pressure; hence, dizziness or lightheadedness may occur, requiring caution while driving or operating hazardous machinery. This medication has the potential for interactions with various drugs; therefore, if taking other medications, it is essential to inform and consult with a doctor or pharmacist. In case of overdose, symptoms such as hypotension and palpitations may appear, so it is essential to strictly adhere to the recommended dosage and immediately inform medical personnel of any abnormal symptoms. The safety and efficacy of this medication in children have not been established, making it not recommended, and the dosage should be adjusted for older adults, considering possible kidney function decline. Store this medication out of reach of children and protect it from moisture, heat, and direct sunlight.

Side effects

Peripheral edema, headache, dizziness, upper respiratory tract infection, nasopharyngitis, urinary tract infection, sialadenitis, leukopenia, thrombocytopenia, bone marrow suppression, neutropenia, agranulocytosis, hemolytic anemia, aplastic anemia, anaphylactic reaction, drug hypersensitivity, hyperkalemia, hypokalemia, loss of appetite, diabetes, hypercalcemia, hyperglycemia, hypomagnesemia, hyponatremia, hypochloremia, hypertriglyceridemia, hypercholesterolemia, hyperuricemia, hypochloremic alkalosis, hyperamylasemia, confusion, depression, apathy, sensitivity to stimuli, agitation, mood changes, sleep disturbances, orthostatic dizziness, syncope, taste disorder, hypertonia, sensory impairment, paresthesia, peripheral neuropathy, drowsiness, fainting, seizures, loss of appetite, tremors, visual disturbances, reduced tear production, worsening of myopia, jaundice, dizziness, tinnitus, palpitations, tachycardia, myocardial infarction, arrhythmia, angina, hypotension, flushing, orthostatic hypotension, vasculitis, thrombosis, embolism, cough, bronchitis, dyspnea, pharyngitis, rhinitis, acute interstitial pneumonia, respiratory distress syndrome, pulmonary edema, diarrhea, nausea, constipation, dry mouth, abdominal pain, changes in bowel movement habits, abdominal distension, dyspepsia, gastritis, gastric discomfort, gastroenteritis, gingival hyperplasia, paralytic ileus, pancreatitis, vomiting, hepatitis, jaundice, acute cholecystitis, hair loss, vascular edema, allergic dermatitis, erythema multiforme, erythema, lupus erythematosus-like skin reaction, pustular rash, exfoliative dermatitis, hyperhidrosis, photosensitivity reaction, pruritus, purpura, Quincke's edema, rash, recurrence of lupus erythematosus, toxic skin necrosis, skin discoloration, Stevens-Johnson syndrome, urticaria, muscle spasms, joint swelling, muscle weakness, ankle edema, arthralgia, arthritis, low back pain, paresis, myalgia, bone pain, frequent urination, acute renal failure, hematuria, urination disorders, nocturia, interstitial nephritis, renal failure, erectile dysfunction, gynecomastia, asthenia, fatigue, chest pain, fever, influenza-like symptoms, lethargy, apathy, edema, pain, facial edema, increased serum creatinine, increased serum urea, increased serum uric acid, decreased serum potassium, increased gamma-glutamyl transferase, increased alanine aminotransferase, increased aspartate aminotransferase, elevated liver enzymes, increased serum creatine phosphokinase, weight loss, weight gain, rhabdomyolysis, chronic malabsorption, intestinal vascular edema, altered consciousness, drug hypersensitivity, epigastric pain, decreased libido, labial edema, asthenia, eczema, limb pain, mild decrease in mean hemoglobin and hematocrit levels, dizziness, benign prostatic hyperplasia, benign salivary gland neoplasm, cerebral infarction, renal failure, abdominal distension, facial flushing, epistaxis, prostatic hyperplasia, prostatitis, dysphagia, papular rash, renal cell dysplasia, acute hearing loss, lymphadenitis, acute respiratory distress syndrome

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or humidity, so it should be stored in a tightly sealed container. It is advisable to maintain storage temperatures between 1°C and 30°C at room temperature to preserve its efficacy and safety for a longer duration.

Appearance and packaging

Appearance

Grayish-red round film-coated tablets

Package unit

30 tablets/box [10 tablets/Alu-Alu*3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.